New cell-based profiling service from RBC and Promega

A new cell-based profiling service for drug discovery announced by Reaction Biology Corporation (RBC), a premier provider of drug discovery services, and Promega Corporation, a worldwide leader in the supply of life science products, will allow more researchers to better prioritize compounds earlier.

Based on Promega NanoBRET™ technology, the service measures direct target engagement of more than 50 kinases in live cells without disruption of cellular membrane integrity and will be expanded to cover more than 200 kinases in the future.

Our customers have been looking for a cell-based service to confirm the biochemical assay data we provide Finally, with the NanoBRET™ service, they can look at highly relevant cell-based results. The Promega assay is unique in cell-based discovery."

Haiching Ma, RBC's Chief Science Officer

NanoBRET™ target engagement assays are still available as kits but RBC is the first provider to create an entire panel as a service, allowing more researchers to access the technology.

"Biochemical kinase assays are a piece of the puzzle, but don't tell the whole story," says Promega Senior Research Scientist Matt Robers.

"By incorporating cellular assays at an earlier stage, researchers can get a better understanding of the impacts of live-cell physiology on the potency and selectivity of their compound. This could save development time and advance chemical matter that has a better chance of having cellular efficacy."

"Researchers have been seeking these more kinase-specific cell-based assays at service providers, and RBC's assay optimization expertise and excellent reputation as a service provider make them the logical choice."

Promega and RBC will launch the new service at the Discovery On Target conference in Boston, September 25-28.  


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Promega Corporation. (2023, June 13). New cell-based profiling service from RBC and Promega. News-Medical. Retrieved on June 15, 2024 from

  • MLA

    Promega Corporation. "New cell-based profiling service from RBC and Promega". News-Medical. 15 June 2024. <>.

  • Chicago

    Promega Corporation. "New cell-based profiling service from RBC and Promega". News-Medical. (accessed June 15, 2024).

  • Harvard

    Promega Corporation. 2023. New cell-based profiling service from RBC and Promega. News-Medical, viewed 15 June 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Promega launches XpressAmp™ Direct Amplification Reagents